AstraZeneca (NYSE:AZN) Q2 core EPS of $1.30, beats by $0.22.
Core operating profit decline 1% to $2.03B.
Revenue +4% to $6.45B, topping consensus of $6.24B.
The company revised FY14 Core EPS guidance to decrease in low double digits at CER, revenue in line at CER from FY13.
The company declared interim dividend of $0.90.